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Abstract 
The Pharmaceutical industry plays a vital role in the socio-economic development of Bangladesh. 
But the net profit of this industry has decreased for the last few years. This study is designed to 
review the financial performance of this industry, to test its strengths and weaknesses. The financial 
performance of this industry is measured in terms of Ratio (Profitability, Liquidity, Solvency and 
Activity ratio) Analysis and in terms of Testing Financial Soundness by using Multivariate 
Discriminate Analysis (MDA) as developed by Prof. Altman. For the source of data mainly relied 
on Annual Reports and official records. It was observed from the study of the financial statement of 
the Pharmaceutical industry that the profit earning capacity, liquidity position, financial position 
and the performance of the most of the Pharmaceuticals are not in sound position and it was also 
observed that the most of the Pharmaceuticals has a lower level position of bankruptcy. The reasons 
behind this position of the industry are inefficiency of financial management, absence of realistic 
goals, strict government regulation and increased cost of raw-materials, labor and overhead. The 
financial performance should be improved immediately. Therefore, the appropriate authority should 
take measures for the removal of the above problems. 
Keywords: Financial Performance, Ratio Analysis, Pharmaceuticals Industry, Multivariate Discriminate 
Analysis (MDA). 
1. Introduction  
Publicly traded companies are the economic pulse of a nation. Their birth, prosperity and demise generally 
reflect the financial condition of the country. A fairly reliable index of an economy in its process of growth 
and development is the rate of growth and decline of publicly traded companies. With the rapid growth of 
trade, commerce and industries, the numbers of publicly traded companies are considerably increasing in 
Bangladesh. These companies play a vital role on the economy of the country. Pharmaceutical is an 
important adjunct of industrialization in the country. Now Pharmaceutical industry is the economic pulse of 
Bangladesh. Its birth, prosperity and demise generally reflect the financial conditions of the country. With 
the rapid growth of trade, commerce and industries the number of listed Pharmaceutical companies is 
considerably increasing in the country. Analyzing the Industrial Life Cycle, it has been found that all of the 
listed companies have just reached the middle stage. No company could reach the maturity stage. In a word, 
the Pharmaceutical industry of the country is just improving.  It is well known that this industry is one of 
the key to earning foreign currency and it plays an important role on the export of the country. On the other 
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hand, most of the internal demand for drugs is fulfilled by the domestic Pharmaceutical industry of the 
country. But Pharmaceutical industry of Bangladesh depends on foreign country for raw-material and 
technology. Now the time to make the Pharmaceutical firms self sufficient for the betterment of the country. 
At this time, performance of manufacturing enterprise, like Pharmaceutical, needs to be measured and 
analyzed. But evaluation of performance is not a regular practice in the country. Against this backdrop this 
study is an attempt to evaluate performance of some selected Pharmaceuticals for the period under study. 
To evaluate the financial performance of the Pharmaceuticals, the technique of financial analysis has been 
applied. Among the various tools of financial analysis the most important one is the ratio analysis. It is very 
helpful to gain valuable insight into the financial position, operation and financial problems of a particulars 
enterprise. Moreover, Multivariate Discriminate Analysis (MDA) is used which is developed by Professor 
Altman to examine the overall financial soundness. Some statistical tools like mean, standard deviation, 
co-efficient of variance and T-test are used to evaluate the performance. 
2. Objectives of the study 
The study is designed to achieve the following objectives: 
(i) To assess the financial performance of the selected Pharmaceuticals firms. 
(ii) To test the financial strengths and weaknesses of selected Pharmaceuticals firms. 
(iii) To pinpoint the causes of poor financial performance and suggest some measures to overcome the 
problems. 
3. Hypothesis 
The research is based on following hypothesis. 
H0: There is no significant difference between the industry mean and the individual firm’s ratio. 
H1: There is significant difference between the industry mean and the individual firm’s ratio. 
4. Methodology of the study 
Data has been taken from a sample of 9 Pharmaceuticals in Bangladesh. For the study only A and B 
category Pharmaceuticals are considered. “A” category Pharmaceutical includes those Pharmaceuticals that 
hold annual general meeting (AGM) and declare minimum 10% dividend regularly. The trading time of 
“A” category Pharmaceutical’s share is T+3. “B” category Pharmaceutical includes those Pharmaceuticals 
that hold annual general meeting (AGM) regularly but declare dividend at a rate below 10% on a regular 
basis. The trading time of “B” category Pharmaceutical’s share is also T+3. “Z” category Pharmaceutical 
includes those Pharmaceuticals that neither hold annual general meeting (AGM) nor declare dividend on a 
regular basis. The trading time of “Z” category Pharmaceutical’s share is T+7. Moreover, the size of the 
Pharmaceuticals, availability of information, and year of establishment are also considered for selecting the 
Pharmaceuticals. The study covers a three year period from 2005-06 to 2007-08. This study is based on 
secondary data. Secondary data are the annual reports of the selected Pharmaceuticals firms and various 
studies made available through library work. The collected data have been tabulated, analyzed and 
interpreted with the help of different financial ratios, Multivariate Discriminate Analysis (MDA) and 
statistical tools like mean, standard deviation (SD), coefficient of variance (CV) and T-test, etc. The 
hypothesis has been tested statistically to arrive at conclusion and policy implication.   
5. Literature Review 
Financial analysis is the process of identifying the financial strengths and weaknesses of the firm by 
properly establishing relationship between the items of the balance sheet and the profit and loss account 
(Pandey, 1991). Analysis of financial statements is of interest to lenders, security analysts, managers and 
others (Prasanna, 1995). Trade creditors are interested in the firm’s ability to meet their claims. Their 
analysis will therefore, confine to the evaluation of the firm’s liquidity position. The suppliers are 
concerned with the firm’s solvency and survival. They analyze the firm’s profitability over time. Long term 
creditors place more emphasis on the firm’s solvency and profitability. The investors are most concerned 
about the firm’s earnings. So, they concentrate on the analysis of the firm’s present and future profitability 
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as well as earning ability and risk (Abu Sina, 1998). Financial ratios are the simplest tools for evaluating 
the financial performance of the firm (Chin-Feng, 2005). One can employ financial ratios to determine a 
firm’s liquidity, profitability, solvency, capital structure and asset turnover. Hannan (1998) used financial 
ratios to show the financial position and performance analysis of Bangladesh Shilpa Bank. He showed that 
techniques of financial analysis can be used in the evaluation of financial position and performance of 
financial institution as well as non financial institutions even Development Financial Institutions (DFI). 
Altman (1968) used financial ratios to predict corporate bankruptcy. He found that the bankruptcy model 
has an accuracy rate of 93% and is very successful in predicting failed and non-failed firms. Sina (1998) 
used financial ratios to test the financial strengths and weaknesses of Khulna Newsprint Mills Ltd. He 
found that due to lack of planning and control of working capital, operational inefficiency, obsolete store, 
ineffective credit policy, increased cost of raw materials, labor and overhead, the position of the company 
was not good. Jahur (1995) used financial ratios to measure operational performance of limited company. 
He used profitability, liquidity, activity and capital structure to measure operational performance. Jahur 
(1996) used Altman’s MDA model to conclude the bankruptcy position of Chittagong Steel Mills Ltd. He 
found that absences of realistic goals, strict govt. regulation are the main reasons for the lowest level of 
bankruptcy. Ohlson (1980) employed financial ratios to predict a firm’s crisis. He found that there are four 
factors affecting a firm’s vulnerability. These factors are the firm’s scale, financial structure, performance 
and liquidity. In the article “The Assessment of Financial and Operating Performance of the Cement 
Industry: A Case Study of Confidence Cement Limited”, Dipak & Milan (2001) found that the investment 
in cement was fairly profitable. Salauddin (2001) examined the profitability of the Pharmaceutical 
Companies of Bangladesh. By using ratio analysis, mean, standard deviation and co-efficient of variation 
he found that the profitability of the Pharmaceuticals sector was very satisfactory in terms of the standard 
norms of return on investment. Hye & Rahman (1997) conducted a research to assess the performance of 
the selected private sector general insurance companies in Bangladesh. The study revealed that the private 
sector insurance companies had made substantial progress. The study found that the insurance companies 
were keeping their surplus funds in the form of fixed deposits with different commercial banks due to 
absence of suitable revenues for investment. Salim & Kabir (1996) examined the financial performance of 
Bangladesh Shipping Corporation. They found that conversion of long-term debt to equity may improve the 
financial performance of Bangladesh Shipping Corporation to a greater extent.  These studies show that 
the ratio analysis and MDA are the good method to evaluate firm performance. The researcher uses these 
tools to measure the financial performance of 9 selected Pharmaceutical firms in this paper. 
 
 
6. Theoretical discussion of Financial Ratio 
Financial analysis offers a system of appraisal and evaluation of a firm’s performance and operations; it is the 
analysis of the financial statement of an enterprise. The analysis of financial statement can be best done by 
various yardsticks of which, the important is known as ratio or percentage analysis. Ratio is a numerical or an 
arithmetical relation between two figures. It is expressed when one figure is divided by another. Accounting 
ratios show inter-relationship which exist among various accounting data. Accounting ratio can be expressed 
in various ways such as, a pure ratio, a rate or a percentage. Ratio analysis is certainly a very admirable device 
because it is simple and it has a predictive value. Management and other users thus, rely substantially on the 
financial ratios based on accounting data for making assessments and predictions of past performance, 
present position and probable future potentials. One important way for diagnosing the financial health is to 
measure the profitability, liquidity, activity and solvency and the level of the bankruptcy of enterprise. 
6.1 Profitability Ratio 
Profitability is a measure of efficiency. The profitability ratios measure the performance of profit of an 
enterprise. In other words the profitability ratios are designed to provide answers to questions such as what is 
the rate of profit?. What is EPS? What is the rate of investment? What is the rate of equity? Is the profit 
earned by the enterprise adequate? What is the dividend payout ratio? What is retention ratio and so on? The 
analysis of the profitability ratio is important for the shareholders, creditors, prospective investors, bankers 
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and the government alike. Gross profit margin ratio, return on investment, net profit margin ratio and 
operating profit ratio can be used to measure the profitability position of the enterprise. 
6.2 Liquidity Ratio 
The liquidity ratios measure the ability of an enterprise to meet its short-term obligations and reflect the 
short-term financial strength of an enterprise. Liquidity is a pre-requisite for the very survival of an 
enterprise. Analysis of liquidity is very important in knowing the liquidity status, movement of funds, idle 
fund (if any) which will not only help financial management to keep the liquidity position of the company  
in order but also make sure of payment to short-term creditors, interested in short-term solvency of the 
company. Liquidity ratios reveal the rate at which fixed and working assets are being converted into cash 
and the time when the cash will be required. Current ratio, quick ratio and working capital to total asset 
ratio can be used to measure the liquidity position of the enterprise. 
6.3 Activity Ratio 
Activity ratios indicate the effectiveness of an enterprise with which different assets are managed and 
utilized in a business. The efficiency in assets management is measured by activity ratio which involves the 
comparisons between the level of sales and investment in various assets accounts, inventories, bills 
receivable, fixed assets and others. The activity can be measured by the use of activity ratios such as 
inventory turnover, fixed assets turnover and total assets turnover.  
6.4 Solvency Ratio 
The long-term solvency of a company is an important aspect to the present and future long-term creditors, 
banks, debenture holders etc. Before sanctioning loan or buying a debenture or preference share, they are 
interested to see whether the company has ability to pay the interest regularly as well as repay the 
installment of the principal on due date or in one lump sum at the time of maturity. The long-run solvency 
of a company can be measured by the use of solvency ratios named debt to total assets, the time interest 
earned and retained earning to total assets. 
7. Findings and Discussions 
7.1 Profitability Ratio 
The tables (01, 02,03,04,05 and 06) depict various financial ratios covering profitability of the selected 
Pharmaceuticals for the period under study. 
(Insert table-01 here) 
 
7.1.1 Gross Profit Margin 
The earnings in terms of sales can be assessed through the profit margin. The gross profit margin reflects 
the effectiveness of pricing policy and of production efficiency. Some authors consider that a profit margin 
ratio ranging from 20% to 30% has been considered as the standard norm for any industrial enterprise. The 
table-01 shows that BXPHARMA he highest average gross profit ratio over the study period. The average 
gross profit ratios range from highest 34.43% in BXPHARMA to lowest 9.42% in BEACONPHAR study is 
to found that the industry average gross profit ratio was 17.69% and the average gross profit ratio of all but 
five samples was below industry average. The co-efficient of variation of gross profit ratios of the samples 
reveals that the variation of gross profit over the years is negligible except two sample companies 
(SQURPHARMA and BXPHARMA) which speaks about the stability of gross profit earning of this sector. 
In view of standard, the gross profit margin of SQURPHARMA , IBNSINA, BXPHARMA, AMBEEPHA 
during the period was higher than standard norm and shown an increasing trend but the ratio for 
ACTIVEFINE, RENETA, BEACONPHAR, BXPHARMA , and PHARMAID was lower than the standard. 
The higher ratio indicates favorable purchasing and markup policies and the ability of management to 
develop sales volume and lower ratio indicates unfavorable purchasing and markup policies and the 
inability of management to develop sales volume. This ratio also indicates that the selected enterprise 
(SQURPHARMA, IBNSINA, BXPHARMA, and AMBEEPHA) seems to be in an advantage position to 
service in the face of falling sales prices, rising cost of production or decline demand for the product. From 
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the calculated value of t it is seen that there is a significant difference in gross profit ratio between industry 
average and individual pharmaceuticals firms except SQURPHARMA and AMBEEPHA. 
(Insert table-02 here) 
 
7.1.2 Net Profit Margin 
The ratio reveals the overall profitability of the concern, that’s why it is very useful to the proprietors and 
prospective investors. It also indicates management efficiency in manufacturing, administrating and selling 
of the products. The table-02 shows that the net profit ratios range from highest 10.75% in 
SQURPHARMA to lowest 13.36 %( negative) in BXPHARMA. SQURPHARMA earned the highest 
average net profit margin (10.75%) and industry average is 1.35%. The calculated ratios in table-02 are all 
very lower position except SQURPHARMA, IBNSINA, RENETA and PHARMAID. Lower position refers 
to the company’s failure to achieve satisfactory return on owners’ equity. It also indicates that the efficiency 
of the samples is very low in position. The position of BXPHARMA is negative. The co-efficient of 
variation of net profit ratios of the samples reveals that the variation of net profit over the years is negligible 
except two sample companies SQURPHARMA (and BXPHARMA) which speaks about the stability of net 
profit earning of this sector. Calculated values of t’ state that there is a significant difference in net profit 
ratio between industry average and 5 individual pharmaceuticals firms (IBNSINA, BXPHARMA, 
RENETA, BEACONPHAR and PHARMAID). 
(Insert table-03 here) 
 
7.1.3 Return on Investment (ROI) 
This ratio measures the profitability of enterprise on total investment. The Planning Commission, 
Government of Bangladesh has declared that the entire existing project in the public sector would have to 
guarantee a fixed return to 7.5% of the investment. This may be considered as the standard norm for the 
industrial enterprise. The table-03 shows that the return on investment on an average for the period under 
study varies from maximum 19.48% in SQURPHARMA to minimum 0.70% in BPL and the industry 
average is 6.67% which is lower than the standard norm of 7.5% . The ratio for BXPHARMA is negative. It 
is seen from the table that ACTIVEFINE, BXPHARMA, RENETA, BEACONPHAR, PHARMAID and 
BPL have a low ratio as compared to the industry average and standard norm, which is indicative of poor 
earning in terms of investment, the return on investment for SQURPHARMA(24.38%), IBNSINA (14.39%) 
and AMBEEPHA (11.16%) should be considered as extremely satisfactory as they are more than the 
industry average ratio and as well as the standard norm and this ratios are indicative of very good 
profitability in terms of investment. ACTIVEFINE, BXPHARMA, RENETA, BEACONPHAR, 
PHARMAID and BPL show a declining trend which indicates the inefficiency of the business as a whole. 
The co-efficient of variation of return on investment ratios of the samples reveals that the variation of return 
on investment over the years is negligible except two sample companies (SQURPHARMA and 
AMBEEPHA) which speaks about the stability of return on investment of this sector. From the calculated 
value of t it is observed that there is a significant difference in return on investment between industry 
average and 4 individual pharmaceuticals firms (ACTIVEFINE, IBNSINA, PHARMAID and BPL). For 
other pharmaceuticals the difference is insignificant.  
(Insert table-04 here) 
 
7.1.4 Operating Profit Ratio 
Operating Profit refers to the profit of an enterprise, which is obtained after deducting all operating 
expenses from gross profit. This ratio establishes the relationship between operating profit and sales. The 
ratio indicates the portion remaining out of every taka worth of sales after all operating cost and expenses 
have been met. It represents the overall earnings of an enterprise and one can get a clear idea about the 
efficiency of an enterprise from its operating profit ratio. The higher the ratio, the better is the overall 
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efficiency of the enterprise. Operating profit ratio ranging 4% to 6% is considered norm for the purpose of 
comparison and control by some authors (Jain and Narang, Jahur, Hye). The table-04 shows that the 
average operating profit ratio of the sample pharmaceuticals ranges from highest 29.02% in BXPHARMA 
to lowest 0.41% in BEACONPHAR. The industry average operating profit ratio is 10.72% and most of the 
companies (5 out of 9) failed to attain the average but most of the companies’(5 out of 9) operating profit 
ratio is more than standard. As to variation of operating profit over the years, it is revealed by the 
coefficient of variance that the variation ranges from 0.033% in BEACONPHAR to 29.259% in 
BXPHARMA. The coefficient of variance of 10.407% and 29.259% indicates inconsistency in the overall 
earnings of SQURPHARMA and BXPHARMA. The negligible variation of 0.631% in ACTIVEFINE, 
2.126% in IBNSINA, 1.659% in RENETA, 0.033% in BEACONPHAR, 3.553% in AMBEEPHA, 0.130% 
in PHARMAID and 0.520% in BPL indicate extremely desirable stability position. From the calculated 
value of t it is observed that there is a significant difference in operating profit ratio between industry 
average and almost all individual pharmaceuticals firms except SQURPHARMA. 
(Insert table-05 here) 
 
7.1.5 Return on Capital Employed 
The most independent ratio for assessment of profitability is the return on capital employed. It reflects the 
overall efficiency with which capital is used. Here, Capital Employed=Equity share capital + Preference 
share capital+ Undistributed profit+ Reserve and Surplus+ Long term Liabilities- Fictitious Assets. A rate 
of return ranging from 11% to 12% on Capital employed may be considered as reasonable for a selected 
enterprise. The table-05 represents the return on capital employed ratio of the sample pharmaceuticals for 
the study period. The table shows that the average returns on capital employed ranges from 1.46% in BPL 
to 13.79% in SQURPHARMA and the average ratio is negative for BXPHARMA (-7.52%).  It appears 
from the table that the industry average return on capital employed is 3.59% which is not satisfactory in 
terms of the standard norm. It is seen from the table that only SQURPHARMA has a high ratio as 
compared with standard norm, IBNSINA, BEACONPHAR, AMBEEPHA and PHARMAID have a high 
ratio as compared to industry average. ACTIVEFINE, BXPHARMA, RENETA and BPL have a ratio lower 
than industry average, which is indicative of poor earning in terms of capital employed. It appears from the 
table that BXPHARMA has the highest variation (43.107%) and AMBEEPHA has the second highest 
variation (27.971%) as indicated by the coefficient of variation which indicates extremely instability in 
their earnings. The variation of this ratio for ACTIVEFINE (0.046%), SQURPHARMA (7.491%), 
IBNSINA (0.946%), RENETA (4.113%), BEACONPHAR (2.369%), PHARMAID (0.575%) and BPL 
(0.033%) should be considered satisfactory. The lower ratios conclude that management should be more 
efficient in using the long term fund of owners and creditors. From the calculated value of t it is observed 
that there is a significant difference in return on capital employed between industry average and 4 
individual pharmaceuticals firms (ACTIVEFINE, SQURPHARMA, BXPHARMA and BPL). For other 
pharmaceuticals the difference is insignificant. 
(Insert table-06 here) 
 
7.1.6 Return on Total Assets 
This ratio is calculated to measure the profit after the tax against the amount invested in total assets to 
ascertain whether assets are being utilized properly or not. Some authors consider 10% to 12% rate of 
return on total assets as reasonable norm for a profitable firms and this may be considered as reasonable 
norm for the selected enterprises. Table -06 shows that the average return on total assets ranges from 0.59% 
in BPL to 7.42% in SQURPHARMA and the average return on total assets for BXPHARMA is negative 
(-3.77%0. It is seen from the table that the average return on total assets is 1.83% which is far away from 
standard norm. The average returns on total assets of all pharmaceuticals are below the standard norm 
which cannot be considered as satisfactory and desirable. The average return on total assets of 
BEACONPHAR (0.70%), BXPHARMA (-3.77%), AMBEEPHA (1.28%) and BPL (0.59%) are below the 
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industry average. The calculated ratios show a decreasing trend for most of the pharmaceuticals during the 
period of study and lower ratios indicate the assets were not being utilized properly during the period. In the 
context of variation of this ratio over the years, it is found that the variation is almost stable. The calculated 
values of t state that there is a significant difference in return on total assets between industry average and 4 
individual pharmaceuticals firms (SQURPHARMA, BEACONPHAR, PHARMAID and BPL). For other 
pharmaceuticals the difference is insignificant. 
7.2 Liquidity Ratio 
The Current Ratio and Quick Ratio, Current Assets to Fixed Assets and Net Working Capital to Total Assets 
are used to assess liquidity position of an enterprise. The tables (07, 08, 09, and10) depict various financial 
ratios covering liquidity of the selected pharmaceuticals for the period under study. 
(Insert table-07 here) 
 
7.2.1 Current Ratio 
This ratio is a measure of the firm’s short term solvency of the firm’s liquidity. It indicates the ability of the 
company to meet its current obligations. If the current ratio is too low, the firm may have difficulty in 
meeting short run commitment as they measure. If the ratio is too high the firm may have an excessive 
investment in current assets or be under utilizing short term credit. Some authors consider 2:1 as standard 
norm for current ratio. Table-07 shows that the industry average current ratio is 0.94:1 which indicates that 
the industry is not able to meet its current obligations from its current assets. The average current ratio 
ranges from 0.57:1 in AMBEEPHA to 1.12:1 in SQURPHARMA. The average current ratios of 
BEACONPHAR (0.61:1), AMBEEPHA (0.57:1) and BPL (0.85:1) are below the industry average as well 
as below the standard norm. The average current ratios of ACTIVEFINE (1.08:1), SQURPHARMA 
(1.12:1), IBNSINA (1.10:1), BXPHARMA (1.06:1), RENETA (1.08:1) and PHARMAID (0.98:1) are 
above the industry average but below the standard norm. It is seen from the table that all these ratios are far 
from standard norm. Therefore it can be said that the liquidity in terms of current ratio had been quite 
inadequate in all the years under study for all the pharmaceuticals. The downward trend of current ratios of 
BXPHARMA, RENETA, BEACONPHAR, AMBEEPHA, PHARMAID and BPL indicate the inefficient 
liquidity management in case of the selected pharmaceuticals, the financial position is very unsatisfactory 
and the companies’ short term solvency is threatened. From the coefficient of variation it is clear that the 
variation of current ratio over time is negligible. From the calculated value of t it is seen that there is a 
significant difference in current ratio between industry average and 4 individual pharmaceuticals firms 
(RENETA, BEACONPHAR, AMBEEPHA, and PHARMAID). For other pharmaceuticals the difference is 
insignificant.  
(Insert table-08 here) 
 
7.2.2 Liquid (Quick or Acid Test) Ratio 
It measures the firm’s ability to meet short term obligations from its most liquid assets. Table-08 shows that 
the industry average of liquid ratio is 0.57:1 which is very lower than the standard (1:1) ratio. The table 
reveals that the average liquid ratio ranges from 0.29:1 in IBNSINA and in BEACONPHAR to 1.28:1 in 
ACTIVEFINE. The average liquid ratios of IBNSINA (0.29:1), RENETA (0.55:1), BEACONPHAR 
(0.29:1), AMBEEPHA (0.38:1) and BPL (0.43:1) are below the industry average as well as far away from 
standard norm and the average ratios of SQURPHARMA (0.64:1), BXPHARMA (0.59:1), and 
PHARMAID (0.70:1) are above the industry average but below the standard norm. It indicates that all 
pharmaceuticals except ACTIVEFINE (average liquid ratio is 1.28:1) are financially very weak and have 
no ability to pay its most immediate liabilities. It is also observed that this position is declining for most of 
the pharmaceuticals and it is the dangerous signal for the companies. In the context of variation of this ratio 
over the years, it is found that the variation is almost stable. From the calculated value of t it is observed 
that there is a significant difference in liquid ratio between industry average and 4 individual 
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pharmaceuticals firms (ACTIVEFINE, IBNSINA, BEACONPHAR and AMBEEPHA). For other 
pharmaceuticals the difference is insignificant. 
(Insert table-09 here) 
 
 
7.2.3 Current Assets to Fixed Assets 
Another criterion for liquidity assessment is the ratio between current assets to fixed assets. This ratio will 
differ from industry to industry and, therefore, no standard can be laid down. A decrease in ratio may mean 
that trading is slack or more mechanization has been put through. The table-09 shows that the industry 
average current asset to fixed assets is 0.78:1. It is seen from the table that the average current assets to 
fixed assets ratio ranges from 0.40:1 in ACTIVEFINE to 1.06:1 in SQURPHARMA and the average ratio 
for ACTIVEFINE (0.40:1), IBNSINA (0.79:1), RENETA (0.51:1), BPL (0.61:1) is lower than industry 
average and the average ratio for SQURPHARMA (1.06:1), BXPHARMA(0.94:1), BEACONPHAR 
(0.89:1), AMBEEPHA (0.92:1) and PHARMAID (0.93:1) is higher than the industry average. The 
calculated ratios show a decreasing trend for some pharmaceuticals which mean that trading is slack or 
more mechanization has been put through in that pharmaceuticals. From the coefficient of variation it is 
clear that the variation of current ratio over time is negligible. From the calculated value of t it is observed 
that there is a significant difference in current assets to fixed assets between industry average and 
ACTIVEFINE. For all other pharmaceuticals the difference is insignificant.  
(Insert table-10 here) 
 
7.2.4 Net Working Capital to Total Assets 
Table-10 shows net working capital to total assets ratios for the selected pharmaceuticals for the study 
period. It is seen from the table that the industry average of net working capital to total assets ratio is 
-0099:1. The table reveals that the average net working capital to total assets ratios of ACTIVEFINE 
(0.0383), SQURPHARMA (0.0543), IBNSINA (0.0403), BXPHARMA (0.0247), RENETA (0.0247) and 
BPL (0.0407) are higher than industry average and the average ratio of BEACONPHAR (-0.2960), 
AMBEEPHA (-0.0004), PHARMAID (-0.0114), are lower than industry average and the figures are 
negative. From the calculated ratios it is clearly seen that the net working capital to total assets ratios are 
very small and for three pharmaceuticals the ratio is negative. Such state of affairs indicates the inability 
and inadequacy of net working capital to cover the total assets of the selected enterprise for the period 
under review. From the coefficient of variation it is seen that the variation of net working capital to total 
assets is insignificant. From the value of t it is observed that there is a significant difference in net working 
capital to total assets between industry average and 3 individual pharmaceuticals firms (RENETA, 
BEACONPHAR and AMBEEPHA). For other pharmaceuticals the difference is insignificant. 
7.3 Activity Ratios 
Activity ratios show the intensity with which the firm uses its assets in generation sales. These ratios 
indicate whether the firm’s investments in current and long-term assets are too small or too large. The 
objective is to have “enough” assets but not “too many”. The tables (11, 12, and13) depict various activity 
ratios of the selected pharmaceuticals for the period under study. 
(Insert table-11 here) 
 
7.3.1 Inventory Turnover Ratio 
This ratio is also known as stock turnover ratio, establishes relationship between sales (or cost of goods 
sold) and the total inventory (or average inventory). A low inventory turnover may indicate an excessive 
investment in inventories a high ratio often means that the firm is running out of stock, resulting in poor 
service to customers. It assists the financial manager in evaluating inventory policy to avoid any danger of 
Journal of Biology, Agriculture and Healthcare     www.iiste.org 
ISSN 2224-3208 (Paper)  ISSN 2225-093X (Online) 
Vol 1, No.2, 2011 
 
33 | P a g e  
www.iiste.org  
over stocking as a prelude to the effective utilization of the resources of the firm. Higher the ratio the better 
it is because it shows that stock is rapidly turned over. The table-11 shows that the industry average 
inventory turnover is 6.45 times. It is seen from the table that the average inventory turnover ratio ranges 
from 1.47 times in BXPHARMA to 19.99 times in ACTIVEFINE. Some authors consider 8 to 9 times of 
inventory turnover ratio as the reasonable norm for an efficient concern. From the study it is seen that the 
average inventory turnover for all selected  pharmaceuticals except three pharmaceuticals, 
ACTIVEFINE(19.99 times), BEACONPHAR (9.52), PHARMAID (8.13), is lower than the industry 
average as well as standard norm which implies excessive inventory levels or a slow moving or obsolete 
inventories. If it is the obsolete inventories then it has to be written off. This will adversely affect the 
working capital and liquidity position of the firm. The calculated ratios indicate that the sale management 
of the selected pharmaceuticals can’t be said to be efficient to sell its product. As to variation of inventory 
turnover over the years, it is revealed by the coefficient of variance that the coefficient of variance of 
17.692% indicates inconsistency in the inventory turnover of BEAACONPHAR. The negligible variation 
of 0.675% in SQURPHARMA, 0.079% in IBNSINA, 0.086% in BXPHARMA, 2.141% in RENETA, 
1.012% in AMBEEPHA, 5.889% in PHARMAID and 1.706% in BPL indicate extremely desirable stability 
position and with a variation of 8.689% in ACTIVEFINE shows a rather satisfactory stability position. The 
values of t state that there is a significant difference in inventory turnover between industry average and 4 
individual pharmaceuticals firms (ACTIVEFINE, SQURPHARMA, IBNSINA and BXPHARMA). For 
other pharmaceuticals the difference is insignificant.  
    (Insert table-12 here) 
                                                                                                                                                                                           
7.3.2 Net Fixed Assets Turnover 
The ratio indicates the extent of generating sales volume in terms of net fixed assets. Some authors consider 
that an ideal fixed assets turnover for an enterprise should be 5 times of net fixed assets and hence this may 
also be considered so far over selected case. Table-12 shows the net fixed assets turnover ratios for the 
selected pharmaceuticals for the study period. From the calculated ratios it is seen that the industry average 
net fixed assets turnover is 1.67 which is far away from the standard. The average ratio ranges from 0.58 
times in BXPHARMA to 4.41 times in BPL. The average ratio of ACTIVEFINE (1.17times), 
SQURPHARMA (1.41times), IBNSINA (1.16 times), BXPHARMA (0.58times), RENETA (0.94 times) 
and AMBEEPHA (1.45 times) is lower than industry average as well as very lower than standard. Only 
three pharmaceuticals, BEACONPHAR (3.87 times), PHARMAID (2.02 times), BPL (4.41 times), have 
average ratio more than industry average but lower than standard. This low level of ratio indicates poor 
sales volume in terms of fixed assets. This indicates an inefficient use of fixed capital. From the coefficient 
of variation it is clear that the variations are very insignificant. From the calculated value of t it is observed 
that there is a significant difference in net fixed assets turnover between industry average and 5 individual 
pharmaceuticals firms (ACTIVEFINE, IBNSINA, BXPHARMA, RENETA and BEACONPHAR). For 
SQURPHARMA, AMBEEPHA, PHARMAID and BPL the difference is insignificant. 
 (Insert table-13 here) 
 
7.3.3 Total Assets Turnover 
Another activity ratio is total assets turnover. This is a measure of the extent of generating sales in terms of 
the total assets. A standard norm of 200% (i.e. 2 times) of this ratio is considered norm by some authors for 
an industrial enterprise. This may also be taken as such for our selected pharmaceuticals. Table-13 reveals 
that the average total assets turnover ratio ranges from 0.30 times in BXPHARMA to 2.04 times in 
BEACONPHAR and the industry average is 0.90 times which is very lower than standard norm. It is seen 
from the table that the average ratio of ACTIVEFINE (0.81 times), SQURPHARMA (0.69 times), 
IBNSINA (0.65 times), BXPHARMA (0.30 times), RENETA (0.62 times) and AMBEEPHA (0.77 times) is 
lower than the industry average as well as standard norm, but the average ratio of BEACONPHAR (2.04 
times) is higher than industry average as well as standard norm and the average ratio of PHARMAID (1.00 
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time), BPL (1.24 times) is higher than the industry average but lower than  standard norm. Such a low 
level of total assets turnover ratio of ACTIVEFINE, SQURPHARMA, IBNSINA, BXPHARMA, RENETA 
and AMBEEPHA indicates that the selected  pharmaceuticals (ACTIVEFINE, SQURPHARMA, 
IBNSINA, BXPHARMA, RENETA, AMBEEPHA, PHARMAID and BPL generate lower taka of sales per 
taka of tangible assets which may be an indication of poor use of fixed and circulating capital. On the other 
hand the position is strong for BXPHARMA, BEACONPHAR. From the coefficient of variation it is seen 
that the variation over time is stable. From the calculated value of t it is observed that there is a significant 
difference in total assets turnover between industry average and 5 individual pharmaceuticals firms 
(SQURPHARMA, IBNSINA, BXPHARMA, RENETA and BEACONPHAR). For other pharmaceuticals 
the difference is insignificant. 
7.4 Solvency Ratios 
Debt-Equity ratio and Debt to Total Assets ratio are commonly used solvency ratios. The tables (14 and 15) 
depict various solvency ratios of the selected pharmaceuticals for the period under study. 
(Insert table-14 here) 
 
 
7.4.1 Debt-Equity Ratio 
Equity represents a “cushion” for share-holders. This is a ratio calculated to measure the relative 
proportions of outsiders’ funds and shareholder’ funds invested in the company. This ratio is also known as 
external-internal equity ratio. The standard ratio is 2:1. The table-14 shows the debt-equity ratio for the 
selected pharmaceuticals for the study period. It is revealed from the table that the average debt-equity ratio 
is 2.01:1. The debt-equity ratio ranges from 0.33:1 in ACTIVEFINE to 7.28:1 in AMBEEPHA. It is seen 
from the table that the average ratio of ACTIVEFINE (0.33:1), SQURPHARMA (1.08:1), IBNSINA 
(0.65:1), RENETA (1.24:1) and BPL (0.65:1) is lower than the industry average as well as standard norm, 
but the average ratio of BXPHARMA (2.27:1), BEACONPHAR (3.19:1), AMBEEPHA (6.23:1) and 
PHARMAID (2.44:1) is higher than the industry average as well as standard norm. These low levels of 
debt-equity ratio of ACTIVEFINE, SQURPHARMA, IBNSINA, RENETA and BPL mean that the claims 
of creditors are lower than those of owners and the company has not liberally used debt to finance its assets. 
It indicates an inefficient financial management. On the other hand the position is strong for BXPHARMA, 
BEACONPHAR, AMBEEPHA and PHARMAID. From the coefficient of variance it is seen that the 
variations of ACTIVEFINE(0.001:1), SQURPHARMA(0.019:1), IBNSINA(0.007:1), 
BXPHARMA(0.047:1), RENETA(0.008:1), BEACONPHAR(0.241:1), AMBEEPHA(0.057:1), 
PHARMAID(0.063:1) and BPL(0.091:1) are very insignificant i.e. the variation is stable. From the 
calculated value of t it is seen that there is a significant difference in debt-equity ratio between industry 
average and 7 individual pharmaceuticals firms (ACTIVEFINE, SQURPHARMA, IBNSINA, RENETA, 
BEACONPHAR, AMBEEPHA and BPL). For other pharmaceuticals (BXPHARMA and PHARMAID) the 
difference is insignificant. 
(Insert table-15 here) 
 
7.4.2 Debt to Total Assets Ratio 
The objective of this ratio is to assign what portion of total assets (debt + equity) is collected from debt. 
Some authors consider that debt to total assets ratio should be 50% for an industrial enterprise. The table-15 
shows the debt to total assets ratio for the selected pharmaceuticals for the study period. It is observed from 
the table that the industry average debt equity ratio is 36% which is lower than the standard norm. It is also 
seen from the table that the average ratio ranges from 7% in ACTIVEFINE to 83% in AMBEEPHA. The 
calculated ratios indicate the claim of creditors is about to very small in percentage to the shareholders of 
ACTIVEFINE (7%), SQURPHARMA (28%), IBNSINA (35%), RENETA (33%), and BEACONPHAR 
(24%), PHARMAID (27% 0 and BPL (13%) Such a lower ratio of debts to total assets of selected 
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pharmaceuticals reveals the fact that they are less dependent on debt rather than on their own capital for 
financing their projects. On the other hand the average ratio of BXPHARMA (75%) and AMBEEPHA 
(83%) is higher than the average as well as the standard norm which indicates that BXPHARMA and 
AMBEEPHA are more dependent on debt rather than their own capital for financing project. From the 
coefficient of variation it is clear that the variation over time is very insignificant for all the selected 
pharmaceuticals. From the calculated value of t it is observed that there is a significant difference in debt to 
total assets between industry average and 6 individual pharmaceuticals firms (ACTIVEFINE, 
BXPHARMA, BEACONPHAR, AMBEEPHA, PHARMAID and BPL). For other pharmaceuticals the 
difference is insignificant. 
8. Testing financial soundness of selected Pharmaceutical Companies: 
After examining profitability, liquidity, activity and solvency of selected Pharmaceutical Companies, now it 
is necessary to examine the overall financial soundness of these companies during the study period. In this 
context Multivariate Discriminate Analysis (MDA) model as developed by Prof. Altman may be considered 
worth while. The said model can give some rough idea about the financial soundness of the selected 
Pharmaceuticals. He developed the following equation for judging the financial soundness of an enterprise.  
Z = 0.012x1 + 0.014x2 + 0.033x3 + 0.006x4 + 0.999x5  
Where; 
           X1: Working Capital / Total Assets 
             X2: Retained earnings / Total Assets 
             X3: Earning before interest & taxes / Total Assets 
             X4: Market value of equity / Total debt 
             X5: Sales / Total Assets 
             Z: Overall index 
In order to test the overall financial soundness of the selected pharmaceuticals, it needs to calculate the 
ratios of working capital to total assets, retained earnings to total assets, earning before interest & taxes to 
total assets, market value of equity to book value of total debt and sales to total assets.  
(Insert table-16 here) 
 
The table-16 depicts the year wise as well as average position of the ratios of working capital to total assets, 
retained earnings to total assets, earning before interest and taxes to total assets, market value of equity to 
total debt and sales to total assets. 
The year wise position of all these ratios excepting market value of equity to total debt had been either 
negative or to low positive. These resulted in poor financial performance of the sample pharmaceuticals 
during study period. It is seen from the table that the average positions of the working capital to total assets 
are 0.058, 0.174, 0.04, 0.021, 0.025, (0.296), (0.0004), (0.012), (0.079) times, the retained earnings to total 
assets ratios are 0.012, 0.074, 0.007, (0.0370, (0.032), (0.344), 0.0103, 0.0045, 0.005 times, the earning 
before interest & taxes to total assets are 0.022, 0.115, 0.092, 0.045, 0.156, 0.052, 0.123, 0.059, 0.024 times, 
the sales to total assets are 0.813, 0.687, 0.647, 0.299, 0.62, 2.04, 0.749, 1.00, 1.227 times for  
ACTIVEFINE , SQURPHAEMA , IBNSINA, BXPHARMA, RENETA, BEACONPHAR, AMBEEPHA, 
PHARMAID and BPL respectively. Such lower positions of these ratios indicate very unsatisfactory 
position. On the other hand the average market value of equity to total debt are 3.072, 0.94, 1.547, 0.443, 
0.813, 0.32, 0.138, 0.414, 1.767 times for  ACTIVEFINE , SQURPHARMA , IBNSINA, BXPHARMA, 
RENETA, BEACONPHAR, AMBEEPHA, PHARMAID and BPL  respectively which indicate 
unsatisfactory position of financial performance of the sample industry. From coefficient of variance it is 
clear that the variance over time is very insignificant for all the pharmaceuticals. 
(Insert table-17 here) 
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The Table-17 shows the year-wise as well as average position of Z’s score of the sample pharmaceuticals 
during the study period. After putting the respective average values of x1, x2, x3, x4 and x5, in the aforesaid 
equations as developed by Prof. Altman, Z score was estimated. The average Z score ranges from 0.298 in 
BXPHARMA to 2.033 in BEACONPHAR and the industry average Z score is 0.909 comparing with Prof. 
Altman’s conclusion that firms with Z score above 2.99 were solvent while those below Z score of 1.81 
were bankrupt.  
Average Z score of sample pharmaceutical ACTIVEFINE (0.832), SQURPHARMA (0.735), IBNSINA 
(0.655), BXPHARMA (0.298), RENETA (0.633), AMBEEPHA (0.754) are lower than the industry average 
as well as the range provided by Prof. Altman. On the other hand average Z score of sample 
pharmaceuticals of PHARMAID (1.004) and BPL (1.243) are higher than the industry average but lower 
than the range provided by Prof. Altman. Only Z score of BEACONPHAR (2.033) exists within the range 
provided by Prof. Altman. The table shows the position of bankruptcy at a lower level during the period for 
all the selected pharmaceuticals except BEACONPHAR. 
It can be concluded that the overall financial soundness of the sample Industry during the study period had 
been worst leading to total bankruptcy of the industry. From the calculated value of t it is observed that 
there is a significant difference in Z score between industry average and 6 individual pharmaceuticals firms 
(SQURPHARMA, IBNSINA, BXPHARMA, RENETA, BEACONPHAR and AMBEEPHA). For other 
pharmaceuticals the difference is insignificant. 
9. Conclusions 
From the discussion it can be concluded that the financial position and operational performance of the most 
of the selected pharmaceuticals were not satisfactory. The inefficiency of financial management may be a 
major cause for such a poor position of the state of affairs. By applying Prof. Altman’s MDA model it is 
seen that the overall financial position of the sample pharmaceuticals was at the lower level of bankruptcy 
except only one pharmaceuticals (BEACONPHAR). The main reasons attributed to such a situation were 
reported to be poor market demands, scarcity of raw materials, high competition, vanished quota system, 
management in attention, lack of realistic goals, strict government regulations, political instability, 
increased price of raw materials and others adverse environmental factors etc. In order to save the 
pharmaceuticals from total bankruptcy the financial performance of the sample pharmaceuticals should be 
improved as early as possible. 
The followings are the recommendations: 
i. The financial management specially purchase, sales and inventory management have to be motivated, 
so that they act all the tasks cordially, efficiently and honestly. 
ii. The Pharmaceuticals should regularly make use of ratio analysis and measure should be taken to 
improve undesirable ratios at least as to the point of industry’s average. 
iii. Qualified, trained and experienced management personnel should be appointed.  
iv. Government regulations should be flexible and policy should be realistic. 
v. Operational efficiency should be increased by reducing cost and wastage and improving operating and 
management performance. Supply of working capital should be adequate. 
vi. Liquidity position of the selected Pharmaceuticals should be improved by reducing current liabilities. 
vii. A reasonable credit policy should be implemented, so that the main portion of profit does not spend in 
payment of fixed charges. 
viii. Accountability and motivation for achievement of performance should be fixed up. 
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Table-01: Gross Profit Margin 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFINE 11 13.56 13.51 12.69 17.69 1.4638 2.143 -5.192* 0.027 
SQURPHARM
A 
22.13 22.84 16.87 20.61 17.69 
3.2612 
10.635 1.553 0.261 
IBNSINA 21.98 21.46 19.89 21.11 17.69 1.0881 1.184 5.444* 0.032 
BXPHARMA 39.03 29.18 35.08 34.43 17.69 4.9571 24.573 5.849* 0.028 
RENETA 9.62 10.12 11.82 10.52 17.69 
1.1533 
1.330 -10.768
** 
0.009 
BEACONPHA
R 
9.70 9.28 9.27 9.42 17.69 
0.2454 
0.060 -58.388
** 
0.000 
AMBEEPHA 18.44 19.90 22.57 20.30 17.69 2.0943 4.386 2.161 0.163 
PHARMAID 14.16 14.25 14.32 14.24 17.69 
0.0802 
0.006 -74.429
** 
0.000 
BPL 16.22 16.23 15 15.82 17.69 0.7073 0.500 -4.588* 0.044 
Source: Annual Report and Official Records of the selected Pharmaceuticals  
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table-02: Net Profit Margin 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFINE 1.80 2.40 2.53 2.24 1.35 0.3894 0.152 3.974 0.058 
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SQURPHARM
A 
13.31 11.13 7.83 10.75 1.35 
2.7590 
7.612 3.978 0.059 
IBNSINA 
3.87 4.67 4.78 4.44 1.35 
0.4967 
0.247 10.775*
* 
0.009 
BXPHARMA (4.01) (23.30) (12.79) (13.36) 1.35 
9.6579 
93.275 -20.639
** 
0.005 
RENETA 2.71 3.35 4.50 3.52 1.35 0.9070 0.823 4.544* 0.050 
BEACONPHA
R 
0.52 0.22 0.30 0.34 1.35 
0.1553 
0.024 -11.19*
* 
0.008 
AMBEEPHA 0.97 0.96 2.28 1.40 1.35 0.7592 0.576 0.122 0.914 
PHARMAID 
2.34 2.50 2.26 2.37 1.35 
0.1222 
0.015 14.410*
* 
0.005 
BPL 0.72 0.52 0.20 0.48 1.35 0.2623 0.069 -5.624* 0.030 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
 
 
 
Table-03: Return on Investment 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFINE 2.57 2.93 3.09 2.86 6.67 0.2663 0.071 -24.756** 0.002 
SQURPHARM
A 
20.72 32.93 19.48 24.38 6.67 7.4333 55.25
4 
4.126 0.054 
IBNSINA 11.79 15.73 15.64 14.39 6.67 2.2492 5.059 5.942* 0.027 
BXPHARMA (1.39) (6.74) (3.19) -3.77 6.67 2.7223 7.411 -6.645* 0.022 
RENETA 3.69 4.79 6.20 4.89 6.67 1.2582 1.583 -2.446 0.134 
BEACONPHA
R 
4.77 2.01 2.21 3.00 
6.67 
1.5390 
2.369 -4.134 0.054 
AMBEEPHA 6.85 8.90 17.72 11.16 
6.67 
5.7757 
33.35
9 
1.345 0.311 
PHARMAID 2.27 2.35 2.45 2.36 6.67 0.0902 0.008 -82.84** 0.000 
BPL 0.75 0.76 0.70 0.74 6.67 0.0321 0.001 -319.69** 0.000 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
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Table-04: Operating Profit Ratio 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFINE 3.92 5.27 5.32 4.84 
10.72 
0.7943 
0.631 -12.83*
* 
0.006 
SQURPHARM
A 
19.63 20.89 14.78 18.43 
10.72 
3.2260 
10.40
7 
4.141 0.054 
IBNSINA 18.09 16.47 15.18 16.58 10.72 1.4581 2.126 6.961* 0.020 
BXPHARMA 29.61 23.34 34.11 29.02 
10.72 
5.4092 
29.25
9 
5.860* 0.028 
RENETA 2.99 4.02 5.55 4.19 10.72 1.2881 1.659 -8.785* 0.013 
BEACONPHA
R 
0.61 0.26 0.35 0.41 
10.72 
0.1818 
0.033 -98.284
** 
0.000 
AMBEEPHA 14.10 16.01 17.87 15.99 10.72 1.8851 3.553 4.845* 0.040 
PHARMAID 2.85 3.05 2.35 2.75 
10.72 
0.3606 
0.130 -38.287
** 
0.001 
BPL 4.23 3.35 4.78 4.12 
10.72 
0.7213 
0.520 -15.848
** 
0.004 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
 
 
Table-05: Return on Capital Employed 
Name of the 
Pharmaceuticals 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFINE 2.03 2.32 2.45 2.27 
3.59 
0.2150 
0.046 -10.66*
* 
0.009 
SQURPHARM
A 
15.02 15.69 10.65 13.79 
3.59 
2.7370 
7.491 6.453* 0.023 
IBNSINA 3.70 5.01 5.60 4.77 3.59 0.9725 0.946 2.102 0.170 
BXPHARMA (2.32) (14.9) (5.35) (7.52) 
3.59 
6.5656 
43.10
7 
-5.932* 0.039 
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RENETA 0.35 3.09 4.31 2.58 3.59 2.0280 4.113 -0.860 0.481 
BEACONPHA
R 
4.77 2.01 2.21 3.00 
3.59 
1.5390 
2.369 -0.668 0.573 
AMBEEPHA 4.06 4.92 13.62 7.53 
3.59 
5.2887 
27.97
1 
1.291 0.326 
PHARMAID 3.70 4.33 5.21 4.41 3.59 0.7584 0.575 1.880 0.201 
BPL 1.53 1.59 1.25 1.46 
3.59 
0.1815 
0.033 -20.361
** 
0.002 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
 
 
 
 
 
Table-06: Return on Total Assets 
Name of the 
Pharmaceutic
als 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFIN
E 
1.61 1.88 2.01 1.83 
1.83 
0.2040 
0.042 0.028 0.980 
SQURPHAR
MA 
9.00 8.27 5.00 7.42 
1.83 
2.1302 
4.538 4.548* 0.045 
IBNSINA 2.31 3.11 3.20 2.87 1.83 0.4899 0.240 3.688 0.066 
BXPHARMA (1.39) (6.74) (3.19) (3.77) 1.83 2.7223 7.411 -3.565 0.070 
RENETA 2.23 3.09 4.31 3.21 1.83 1.0452 1.092 2.287 0.149 
BEACONPH
AR 
1.04 0.46 0.61 0.70 
1.83 
0.3011 
0.091 -6.482* 0.023 
AMBEEPHA 0.82 1.02 2.00 1.28 1.83 0.6315 0.399 -1.509 0.270 
PHARMAID 2.12 2.26 2.45 2.28 1.83 0.1656 0.027 4.671* 0.043 
BPL 0.75 0.76 0.25 0.59 1.83 0.2916 0.085 -7.385* 0.018 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
 
 
Table-07: Current Ratio 
Name of the 
Pharmaceutic
als  
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
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ACTIVEFIN
E 
1.26:1 1.51:1 1.74:1 1.08:1 0.94:1 0.241 
0.058 
4.064 0.056 
SQURPHAR
MA 
1.05:1 1.09:1 1.21:1 1.12:1 0.94:1 0.083 
0.007 
3.675 0.067 
IBNSINA 0.98:1 1.13:1 1.19:1 1.10:1 0.94:1 0.108 0.012 2.562 0.125 
BXPHARMA 1.27:1 0.98:1 0.92:1 1.06:1 0.94:1 0.187 0.035 1.080 0.393 
RENETA 1.09:1 1.08:1 1.06:1 1.08:1 0.94:1 0.015 
0.001 
15.497*
* 
0.004 
BEACONPH
AR 
0.70:1 0.60:1 0.52:1 0.61:1 0.94:1 0.090 
0.008 
-6.402* 0.024 
AMBEEPHA 0.58:1 0.56:1 0.56:1 0.57:1 0.94:1 0.012 
0.001 
-56.00*
* 
0.000 
PHARMAID 0.98:1 0.97:1 0.98:1 0.98:1 0.94:1 0.006 0.001 11.00** 0.008 
BPL 0.98:1 0.90:1 0.67:1 0.85:1 0.94:1 0.161 0.026 -0.969 0.435 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
 
 
 
 
 
 
 
 
 
 
 
Table-08: Liquid/ Quick/ Acid Test Ratio 
Name of the 
Pharmaceutic
als 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFIN
E 
1.06:1 1.31:1 1.47:1 1.28:1 
0.57:1 
0.207 0.043 
5.951* 0.027 
SQURPHAR
MA 
0.58:1 0.66:1 0.69:1 0.64:1 
0.57:1 
0.057 0.003 
2.234 0.155 
IBNSINA 0.35:1 0.34:1 0.18:1 0.29:1 0.57:1 0.096 0.009 -5.084* 0.037 
BXPHARMA 0.68:1 0.52:1 0.57:1 0.59:1 0.57:1 0.082 0.007 0.423 0.713 
RENETA 0.51:1 0.66:1 0.49:1 0.55:1 0.57:1 0.093 0.009 -0.311 0.783 
BEACONPH 0.32:1 0.23:1 0.33:1 0.29:1 0.57:1 0.055 0.003 -8.701* 0.013 
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AR 
AMBEEPHA 0.42:1 0.37:1 0.34:1 0.38:1 0.57:1 0.040 0.002 -8.286* 0.014 
PHARMAID 0.59:1 0.76:1 0.74:1 0.70:1 0.57:1 0.093 0.009 2.361 0.142 
BPL 0.47:1 0.50:1 0.32:1 0.43:1 0.57:1 0.096 0.009 -2.514 0.128 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
 
 
Table-09: Current Assets to Fixed Assets 
Name of the 
Pharmaceutic
als 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFIN
E 
0.35:1 0.40:1 0.46:1 0.40:1 0.78:1 
0.055 0.003 
-11.846
** 
0.007 
SQURPHAR
MA 
0.66:1 0.96:1 1.56:1 1.06:1 
0.78:1 
0.458 0.211 
1.058 0.401 
IBNSINA 0.58:1 0.74:1 1.04:1 0.79:1 0.78:1 0.234 0.055 0.049 0.965 
BXPHARMA 1.04:1 1.16:1 0.61:1 0.94:1 0.78:1 0.289 0.084 0.938 0.447 
RENETA 0.44:1 0.43:1 0.66:1 0.51:1 0.78:1 0.130 0.017 -3.597 0.069 
BEACONPH
AR 
1.22:1 0.85:1 0.60:1 0.89:1 
0.78:1 
0.312 0.098 
0.611 0.604 
AMBEEPHA 0.82:1 0.90:1 1.03:1 0.92:1 0.78:1 0.106 0.011 2.233 0.155 
PHARMAID 0.79:1 0.90:1 1.09:1 0.93:1 0.78:1 0.152 0.023 1.674 0.236 
BPL 0.50:1 0.74:1 0.60:1 0.61:1 0.78:1 0.121 0.015 -2.395 0.139 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
 
 
 
 
 
 
 
 
 
 
 
 
Table-10: Net Working Capital to Total Assets 
Journal of Biology, Agriculture and Healthcare     www.iiste.org 
ISSN 2224-3208 (Paper)  ISSN 2225-093X (Online) 
Vol 1, No.2, 2011 
 
44 | P a g e  
www.iiste.org  
Name of the 
Pharmaceutic
als 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFIN
E 
(0.005) 0.04 0.08 0.0383 (0.0099) 
0.0425 
0.002 1.965 0.188 
SQURPHAR
MA 
0.019 0.04 0.104 0.0543 (0.0099) 
0.0443 
0.002 2.513 0.129 
IBNSINA (0.006) 0.047 0.080 0.0403 (0.0099) 0.0434 0.002 2.006 0.183 
BXPHARMA 0.018 (0.012) (0.035) 0.0203 (0.0099) 0.0266 0.001 0.020 0.986 
RENETA 0.026 0.024 0.024 0.0247 (0.0099) 
0.0012 
0.000 54.684*
* 
0.000 
BEACONPH
AR 
(0.233) (0.307) (0.348) (0.296
0) (0.0099) 0.0583 
0.003 -8.508* 0.014 
AMBEEPHA (0.0003) (0.0004) (0.0004) (0.000
4) (0.0099) 0.0001 
0.000 4.465* 0.050 
PHARMAID (0.008) (0.0140) (0.0122) (0.011
4) (0.0099) 0.0031 
0.000 -0.821 0.498 
BPL (0.008) (0.05) 0.18 0.0407 (0.0099) 0.1225 0.015 0.716 0.548 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
 
 
Table-11: Inventory Turnover 
Name of the 
Pharmaceutic
als 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFIN
E 
22.30 21.00 16.67 19.99 
6.45 
2.9478 
8.689 7.956* 0.015 
SQURPHAR
MA 
4.09 4.26 2.76 3.70 
6.45 
0.8214 
0.675 -5.792* 0.029 
IBNSINA 1.66 2.09 1.56 1.77 
6.45 
0.2816 
0.079 -28.785
** 
0.001 
BXPHARMA 1.52 1.16 1.74 1.47 
6.45 
0.2928 
0.086 -29.439
** 
0.001 
RENETA 3.64 5.64 2.79 4.03 6.45 1.4632 2.141 -2.873 0.103 
BEACONPH
AR 
6.75 7.45 14.36 9.52 
6.45 
4.2062 
17.69
2 
1.264 0.334 
AMBEEPHA 3.82 5.70 4.14 4.55 6.45 1.0058 1.012 -3.266 0.082 
PHARMAID 5.44 8.81 10.15 8.13 6.45 2.4268 5.889 1.201 0.353 
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BPL 3.35 5.67 5.55 4.86 6.45 1.3062 1.706 -2.113 0.169 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
 
 
 
 
 
 
Table-12: Net Fixed Assets Turnover 
Name of the 
Pharmaceutic
als 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFIN
E 
1.22 1.12 1.17 1.17 
1.67 
0.0500 
0.003 -17.321
** 
0.003 
SQURPHAR
MA 
1.13 1.45 1.64 1.41 1.67 0.2577 0.066 -1.770 0.219 
IBNSINA 0.95 1.16 1.36 1.16 1.67 0.2050 0.042 -4.337* 0.049 
BXPHARMA 0.71 0.63 0.40 0.58 
1.67 
0.1609 
0.026 -11.731
** 
0.007 
RENETA 0.86 0.96 1.00 0.94 
1.67 
0.0721 
0.005 -17.534
** 
0.003 
BEACONPH
AR 
4.43 3.96 3.23 3.87 
1.67 
0.6047 
0.366 6.311* 0.024 
AMBEEPHA 1.29 1.56 1.51 1.45 1.67 0.1436 0.021 -2.613 0.121 
PHARMAID 1.72 1.71 2.63 2.02 1.67 0.5283 0.279 1.147 0.370 
BPL 2.34 2.87 2.03 4.41 1.67 0.4248 0.180 3.031 0.094 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
 
Table-13: Total Assets Turnover 
Name of the  
Pharmaceutic
als 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFIN
E 
0.89 0.76 0.79 0.81 
0.90 
0.0681 
0.005 -2.205 0.158 
SQURPHAR
MA 
0.68 0.74 0.64 0.69 
0.90 
0.0503 
0.003 -7.341* 0.018 
IBNSINA 0.60 0.67 0.67 0.65 0.90 0.0404 0.002 -10.857 0.008 
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** 
BXPHARMA 0.35 0.29 0.25 0.30 
0.90 
0.0503 
0.003 -20.762
** 
0.002 
RENETA 0.59 0.67 0.60 0.62 
0.90 
0.0436 
0.002 -11.126
** 
0.008 
BEACONPH
AR 
1.99 2.13 2.00 2.04 
0.90 
0.0781 
0.006 25.281*
* 
0.002 
AMBEEPHA 0.72 0.84 0.74 0.77 0.90 0.0643 0.004 -3.592 0.070 
PHARMAID 0.90 0.87 1.23 1.00 0.90 0.1997 0.040 0.867 0.477 
BPL 1.04 1.40 1.27 1.24 0.90 0.1823 0.033 3.199 0.085 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
 
 
 
 
Table-14: Debt-Equity Ratio 
Name of the 
Pharmaceutic
als 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFIN
E 
0.35 0.32 0.31 0.33 2.01 0.021 0.001 -140.062
** 
0.000 
SQURPHAR
MA 
1.14 1.18 0.92 1.08 2.01 0.140 0.019 -11.506*
* 
0.007 
IBNSINA 0.60 0.61 0.75 0.65 2.01 0.084 0.007 -28.019*
* 
0.001 
BXPHARMA 2.03 2.45 2.33 2.27 2.01 0.216 0.047 2.082 0.173 
RENETA 1.29 1.14 1.29 1.24 2.01 0.087 0.008 -15.400*
* 
0.004 
BEACONPH
AR 
3.59 3.33 2.64 3.19 2.01 0.491 0.241 4.151* 0.053 
AMBEEPHA 6.97 7.44 7.28 7.23 2.01 0.239 0.057 37.837** 0.001 
PHARMAID 2.21 2.48 2.71 2.44 2.01 0.251 0.063 3.161 0.087 
BPL 0.39 0.58 0.98 0.65 2.01 0.301 0.091 -7.822* 0.016 
Source: Annual Report and Official Records of the selected Pharmaceuticals  
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
  
Table-15: Debt to Total Assets Ratio 
Name of the 2005-06 2006-07 2007-08 Mean Industry S.D C.V t value Sig.(2 
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Pharmaceutic
als 
Mean tailed) 
ACTIVEFIN
E 
0.08 0.07 0.06 0.07 
0.36 
0.010
0 
0.000 50.229** 0.000 
SQURPHAR
MA 
0.30 0.31 0.24 0.28 
0.36 
0.037
9 
0.001 -3.507 0.073 
IBNSINA 0.35 0.36 0.34 0.35 
0.36 
0.010
0 
0.000 -1.732 0.225 
BXPHARMA 0.74 0.76 0.74 0.75 
0.36 
0.011
5 
0.000 58.00** 0.000 
RENETA 0.36 0.33 0.30 0.33 
0.36 
0.030
0 
0.001 -1.732 0.225 
BEACONPH
AR 
0.20 0.25 0.27 0.24 
0.36 
0.036
1 
0.001 -5.765* 0.029 
AMBEEPHA 0.82 0.83 0.83 0.83 
0.36 
0.005
8 
0.000 140.00** 0.000 
PHARMAID 0.30 0.27 0.24 0.27 
0.36 
0.030
0 
0.001 -5.196* 0.035 
BPL 0.13 0.17 0.10 0.13 
0.36 
0.035
1 
0.001 -11.179*
* 
0.008 
Source: Annual Report and Official Records of the selected Pharmaceuticals 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
 
 
 
 
 
Table: 16 (Ratios for Testing Financial Soundness) 
Ratios ACTI
VEFIN
E 
SQU
RPH
ARM
A 
IBNS
INA 
BXPH
ARM
A 
RENETA BEACO
NPHAR 
AMBEE
PHA  
PHARM
AID 
BPL Year 
Working 
Capital to 
Total 
Assets (in 
time) 
(0.005) 
0.040 
0.080 
0.038 
0.042 
0.002 
0.019 
0.401 
0.104 
0.174 
0.200 
0.040 
(0.00
7) 
0.047 
0.080 
0.04 
0.044 
0.002 
0.108 
(0.012) 
(0.035) 
0.021 
0.077 
0.006 
0.026 
0.024 
0.024 
0.025 
0.001 
0.000 
(0.233) 
(0.307) 
(0.348) 
(0.296) 
0.0583 
0.0034 
(0.0003) 
(0.0004) 
(0.0004) 
(0.0004) 
0.00001 
0.00000 
(0.008) 
(0.014) 
(0.012) 
(0.012) 
0.0031 
0.0000 
(0.008) 
(0.05) 
(0.18) 
(0.079) 
0.0897 
0.0081 
2005-06 
2006-07 
207-08 
Mean 
S. D. 
C. V. 
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Retained 
Earnings to 
Total 
Assets  (in 
time) 
0.007 
0.012 
0.017 
0.012 
0.005 
0.000 
0.09 
0.083 
0.050 
0.074 
0.021 
0.001 
0.016 
0.001 
0.003 
0.007 
0.008 
0.000 
(0.014) 
(0.067) 
(0.032) 
(0.037) 
0.027 
0.001 
(0.039) 
(0.036) 
(0.022) 
(0.032) 
0.009 
0.000 
(0.314) 
(0.329) 
(0.390) 
(0.344) 
0.041 
0.002 
0.0067 
0.0079 
0.0164 
0.0103 
0.0053 
0.0000 
0.0028 
0.0052 
0.0056 
0.0045 
0.0015 
0.0000 
0.008 
0.006 
0.002 
0.005 
0.003 
0.000 
2005-06 
2006-07 
207-08 
Mean 
S. D. 
C. V. 
Earning 
before 
interest and 
taxes to 
Total 
Assets (in 
time) 
0.019 
0.022 
0.024 
0.022 
0.003 
0.000 
0.124 
0.129 
0.092 
0.115 
0.020 
0.001 
0.078 
0.103 
0.095 
0.092 
0.013 
0.000 
0.077 
0.024 
0.036 
0.045 
0.028 
0.001 
0.37 
0.047 
0.051 
0.156 
0.185 
0.342 
0.048 
0.050 
0.057 
0.052 
0.005 
0.000 
0.099 
0.132 
0.137 
0.123 
0.021 
0.001 
0.046 
0.067 
0.064 
0.059 
0.011 
0.000 
0.030 
0.034 
0.008 
0.024 
0.014 
0.000 
2005-06 
2006-07 
207-08 
Mean 
S. D. 
C. V. 
Market 
value of 
equity to 
Total Debt 
(in time)  
2.86 
3.125 
3.23 
3.072 
0.191 
0.037 
0.88 
0.85 
1.09 
0.94 
0.131 
0.017 
1.67 
1.64 
1.33 
1.547 
0.188 
0.035 
0.49 
0.41 
0.43 
0.443 
0.042 
0.002 
0.78 
0.88 
0.78 
0.813 
0.058 
0.003 
0.28 
0.30 
0.38 
0.32 
0.053 
0.003 
0.143 
0.134 
0.137 
0.138 
0.005 
0.000 
0.471 
0.403 
0.369 
0.414 
0.052 
0.003 
2.56 
1.72 
1.02 
1.767 
0.771 
0.594 
2005-06 
2006-07 
207-08 
Mean 
S. D. 
C. V. 
Sales to 
Total Asset 
(in time) 
0.89 
0.76 
0.79 
0.813 
0.068 
0.005 
0.68 
0.74 
0.64 
0.687 
0.050 
0.003 
0.59 
0.68 
0.67 
0.647 
0.049 
0.002 
0.35 
0.29 
0.25 
0.297 
0.050 
0.003 
0.59 
0.67 
0.60 
0.62 
0.043 
0.002 
1.99 
2.13 
2.00 
2.04 
0.078 
0.006 
0.709 
0.819 
0.721 
0.749 
0.060 
0.004 
0.90 
0.87 
1.23 
1.00 
0.199 
0.040 
1.04 
1.40 
1.24 
1.227 
0.180 
0.032 
2005-06 
2006-07 
207-08 
Mean 
S. D. 
C. V. 
 
Source: Annual Report and Official Records of the selected Pharmaceuticals industry, (2005-2008) 
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Table: 17 (Analysis of Z score) 
Name of the 
Pharmaceutic
als 
2005-06 2006-07 2007-08 Mean Industry 
Mean 
S.D C.V t value Sig.(2 
tailed) 
ACTIVEFIN
E 
0.907 0.779 0.810 0.832 0.909 
0.067 
0.005 -1.997 0.184 
SQURPHAR
MA 
0.690 0.754 0.761 0.735 0.909 
0.039 
0.002 -7.702* 0.016 
IBNSINA 0.602 0.683 0.680 0.655 0.909 0.046 0.002 -9.580* 0.011 
BXPHARMA 0.354 0.290 0.251 0.298 0.909 0.052 0.003 -20.789** 0.002 
RENETA 0.606 0.676 0.610 0.633 0.909 0.039 0.002 -12.264** 0.007 
BEACONPH
AR 
1.986 2.122 1.992 2.033 0.909 
0.077 
0.006 25.342** 0.002 
AMBEEPHA 0.713 0.823 0.726 0.754 0.909 0.060 0.004 -4.466* 0.047 
PHARMAID 0.903 0.876 1.233 1.004 0.909 0.199 0.039 0.828 0.495 
BPL 1.065 1.414 1.240 1.243 0.909 0.175 0.031 3.282 0.082 
 
*Significant at the 0.05 level (2-tailed). ** Significant at the 0.01 level (2-tailed) 
 
 
Table: 18 List of Pharmaceuticals under study: 
 
Name of the Pharmaceuticals Short name used 
Active Fine Chemicals Limited ACTIVEFINE 
Square Pharmaceuticals Limited SQURPHARMA 
The Ibn Sina Pharmaceuticals ltd. IBNSINA 
Beximco Pharma BXPHARMA 
Renata Ltd. RENATA 
Beasel Pharmaceuticals Limited BEACONPHAR 
Ambee Pharma AMBEEPHA 
Pharma Aids PHARMAID 
Beacon Pharmaceuticals Limited BPL 
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